Figure 4. IL-22 ameliorated liver injury during viral hepatitis.

(A) B6 mice were i.v. injected with 3 × 10⁹ pfu of AdLacZ, followed by i.p. injection with 5 μg recombinant IL-22 (rIL-22) or PBS (control) on 1, 3 and 5 dpi. Mice were harvested at 6 dpi. Serum ALT and AST levels were measured. (B) WT and IL-22 KO mice were i.v. injected with 1 × 10⁹ pfu of AdLacZ and sacrificed at 6 dpi. Serum ALT and AST were detected. (C) Numbers of splenocytes and IHLs, as well as the (D) percentages and total numbers of IFN-γ-producing CD4⁺ and CD8⁺ T cells. The experiment was repeated three times independently, and a representative graph is shown (3–8 mice/group). *p < 0.05, **p <0.01, N.S. no statistical difference.